- Home
- FEBO vs ASBP Comparison
FEBO vs ASBP Comparison
Compare FEBO & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- ASBP
- Stock Information
- Founded
- FEBO 1993
- ASBP 2021
- Country
- FEBO Hong Kong
- ASBP United States
- Employees
- FEBO N/A
- ASBP N/A
- Industry
- FEBO
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- ASBP Health Care
- Exchange
- FEBO Nasdaq
- ASBP Nasdaq
- Market Cap
- FEBO 12.7M
- ASBP 11.9M
- IPO Year
- FEBO 2023
- ASBP N/A
- Fundamental
- Price
- FEBO $1.09
- ASBP $0.28
- Analyst Decision
- FEBO
- ASBP
- Analyst Count
- FEBO 0
- ASBP 0
- Target Price
- FEBO N/A
- ASBP N/A
- AVG Volume (30 Days)
- FEBO 5.5K
- ASBP 4.2M
- Earning Date
- FEBO 07-07-2025
- ASBP 08-24-2025
- Dividend Yield
- FEBO N/A
- ASBP N/A
- EPS Growth
- FEBO N/A
- ASBP N/A
- EPS
- FEBO N/A
- ASBP N/A
- Revenue
- FEBO $17,110,653.00
- ASBP N/A
- Revenue This Year
- FEBO N/A
- ASBP N/A
- Revenue Next Year
- FEBO N/A
- ASBP N/A
- P/E Ratio
- FEBO N/A
- ASBP N/A
- Revenue Growth
- FEBO 11.58
- ASBP N/A
- 52 Week Low
- FEBO $0.93
- ASBP $0.22
- 52 Week High
- FEBO $17.68
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- FEBO 45.42
- ASBP N/A
- Support Level
- FEBO $1.06
- ASBP N/A
- Resistance Level
- FEBO $1.15
- ASBP N/A
- Average True Range (ATR)
- FEBO 0.06
- ASBP 0.00
- MACD
- FEBO 0.00
- ASBP 0.00
- Stochastic Oscillator
- FEBO 39.47
- ASBP 0.00
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care c principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.